{"id":"comirnaty-original-omicron-ba-1","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain"},{"rate":"30-50","effect":"Fatigue"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Myalgia"},{"rate":"10-20","effect":"Fever"},{"rate":"10-20","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Comirnaty Original/Omicron BA.1 is a modified version of the original Comirnaty vaccine that includes mRNA sequences encoding spike proteins from both the ancestral SARS-CoV-2 strain and the Omicron BA.1 variant. When administered, the mRNA is translated into spike proteins that stimulate both humoral and cellular immune responses, providing broader protection against circulating variants. This bivalent approach aims to improve vaccine effectiveness against evolving viral strains.","oneSentence":"This bivalent mRNA vaccine encodes spike proteins from both the original SARS-CoV-2 strain and the Omicron BA.1 variant to elicit immune responses against multiple viral lineages.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:47.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in individuals 12 years of age and older (booster dose)"}]},"trialDetails":[{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT05749926","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-16","conditions":"Vaccine Reaction, COVID-19","enrollment":248}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comirnaty Original/Omicron BA.1","genericName":"Comirnaty Original/Omicron BA.1","companyName":"Jules Bordet Institute","companyId":"jules-bordet-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"This bivalent mRNA vaccine encodes spike proteins from both the original SARS-CoV-2 strain and the Omicron BA.1 variant to elicit immune responses against multiple viral lineages. Used for COVID-19 prevention in individuals 12 years of age and older (booster dose).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}